Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Prostate05: Saruparib + ARPI in mHSPC
NCT07711002Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 21
01
Overview
A Phase 3 trial of saruparib in prostate cancer (PCa), sponsored by AstraZeneca. Started Sep 2026; status: recruiting.
02
Drugs
saruparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07711002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711002.